Viral hepatitis
disease diseaseOn this page
Also known as Hepatitis viralunspecified viral hepatitis with hepatic comaviral hepatitis with hepatic comaviral human hepatitisViruses caused hepatitisViruses hepatitis
Summary
Viral hepatitis (MONDO:0006011) is a disease (an umbrella term covering 6 Mondo subtypes) with 2 GWAS associations across 19 studies and 21 clinical trials. Top therapeutic interventions include entecavir anhydrous, bulevirtide, and tenofovir alafenamide. A subtype of hepatitis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Umbrella term: 6 Mondo subtypes
- GWAS associations: 2
- Clinical trials: 21
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | viral hepatitis |
| Mondo ID | MONDO:0006011 |
| EFO | EFO:0004196 |
| MeSH | D006525 |
| DOID | DOID:1884 |
| ICD-10-CM | B15-B19 |
| ICD-11 | 985510409 |
| NCIT | C35124 |
| SNOMED CT | 3738000 |
| UMLS | C0042721 |
| MedGen | 22652 |
| Is cancer (heuristic) | no |
Also known as: Hepatitis viral · unspecified viral hepatitis with hepatic coma · viral Hepatitis · viral hepatitis with hepatic coma · viral human hepatitis · Viruses caused hepatitis · Viruses hepatitis
Data availability: 2 GWAS associations (19 studies).
Disease family
This is a subtype of hepatitis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › digestive system disorder › hepatobiliary disorder › liver disorder › hepatitis › viral hepatitis
Related subtypes (8): alcoholic hepatitis, drug-induced hepatitis, granulomatous hepatitis, hepatic tuberculosis, metabolic dysfunction-associated steatohepatitis, autoimmune hepatitis, fulminant viral hepatitis, idiopathic peliosis hepatis
Subtypes (6): Epstein-Barr virus hepatitis, hepatitis C virus infection, hepatitis B virus infection, hepatitis E virus infection, hepatitis D virus infection, hepatitis A virus infection
Genetics & variants
GWAS landscape
2 GWAS associations across 19 studies. Top hits map to 0 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| rs28891489 | 6e-35 | HLA-DQB1 - MTCO3P1 | ? | |
| chr11:112869404 | 7e-12 | T | 0.07 |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST90475552 | Verma A | 2024 | 21,092 | 425,186 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90477054 | Verma A | 2024 | 14,472 | 105,436 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90480967 | Verma A | 2024 | 14,472 | 105,436 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90651160 | Liu TY | 2025 | 13,641 | 190,942 | Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population. |
| GCST90477053 | Verma A | 2024 | 4,141 | 54,861 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90473057 | UK Biobank Whole-Genome Sequencing Consortium | 2025 | 3,183 | 455,257 | Whole-genome sequencing of 490,640 UK Biobank participants. |
| GCST90473062 | UK Biobank Whole-Genome Sequencing Consortium | 2025 | 1,234 | 457,206 | Whole-genome sequencing of 490,640 UK Biobank participants. |
| GCST90435525 | Zhou W | 2018 | 1,215 | 403,316 | Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. |
| GCST90077702 | Backman JD | 2021 | 979 | 330,775 | Exome sequencing and analysis of 454,787 UK Biobank participants. |
| GCST90081688 | Backman JD | 2021 | 979 | 330,775 | Exome sequencing and analysis of 454,787 UK Biobank participants. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 0 |
| Tier 2: splice/UTR | 0 |
| Tier 3: regulatory | 0 |
| Tier 4: intronic/intergenic | 2 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 2 |
| low_freq (0.01-0.05) | 0 |
| rare (<0.01) | 0 |
| unknown | 0 |
Functional consequences
| Consequence | Count |
|---|---|
| intergenic_variant | 1 |
| unknown | 1 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| rs28891489 | 6 | 32682585 | T>A,C | 0.05 | intergenic_variant | HLA-DQB1 - MTCO3P1 | 6e-35 | Tier 4: intronic/intergenic |
| chr11:112869404 | 0.399 | 7e-12 | Tier 4: intronic/intergenic |
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated or in trials for this disease
No drug has an approved disease-direct ChEMBL indication for this disease.
1 drug in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.
| Drug | Highest phase |
|---|---|
| Silybin A | Phase 2 |
Clinical trials & evidence
Clinical trials
Clinical trials: 21.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 16 |
| PHASE4 | 2 |
| PHASE3 | 2 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03933384 | PHASE4 | RECRUITING | Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B |
| NCT01195181 | PHASE4 | COMPLETED | Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice. |
| NCT06903338 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection |
| NCT07128550 | PHASE3 | RECRUITING | A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide |
| NCT07142811 | PHASE2 | ACTIVE_NOT_RECRUITING | A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection |
| NCT05686785 | Not specified | RECRUITING | Agreement and Reliability of Transient Elastography |
| NCT06904820 | Not specified | RECRUITING | Acceptability and Feasibility of Simultaneous Screening for Viral Hepatitis B, C and HIV Among Drug Users and Vulnerable Populations, in Non-conventional Structures Outside the Walls by Dual Screening Method RTDs and FibroScan® |
| NCT00689546 | Not specified | UNKNOWN | Acute Viral Hepatitis and Diabetes Mellitus |
| NCT01082419 | Not specified | COMPLETED | Acoustic Radiation Force Impulse Imaging (ARFI) : a New Technique to Assess Liver Elasticity |
| NCT01476995 | Not specified | COMPLETED | Prognostic Indicators as Provided by the EPIC ClearView |
| NCT01766895 | Not specified | UNKNOWN | Long-term Follow Up of Viral Hepatitis in Uremic Patients in Taiwan |
| NCT01988753 | Not specified | COMPLETED | Non-invasive Biomarkers of Fibrosis in Pediatric Liver Diseases |
| NCT03743272 | Not specified | COMPLETED | Repeatability and Reproducibility of Multiparametric MRI |
| NCT04062253 | Not specified | COMPLETED | Addressing the Cascade of Care in Vulnerable Populations With Poor Access to Healthcare in Madrid |
| NCT04113915 | Not specified | UNKNOWN | Viral Hepatitis B and C Infection in Patients With Idiopathic Thrombocytopenic Purpura Treated With Triple Therapy |
| NCT04222803 | Not specified | SUSPENDED | VIRal Hepatitis and GAllstone Disease Study |
| NCT04304612 | Not specified | UNKNOWN | A Cost Effective and Time Saving Blood Test to Detect Six Human Bloodborne Infectious Diseases |
| NCT04371276 | Not specified | COMPLETED | Seroepidemiology of Viral Hepatitis in Hong Kong |
| NCT05117541 | Not specified | COMPLETED | Social-environmental, Psychosocial, Behavioral, Clinical and Biological Drivers of Disparities in Liver Disease Progression Among Korean American With Chronic Hepatitis B Infection |
| NCT05207163 | Not specified | UNKNOWN | Continuing Medical Education to Improve Knowledge of Viral Hepatitis B-C in Primary Healthcare Workers |
| NCT06360484 | Not specified | COMPLETED | Prevalence and Clinical Characterization of Hepatitis D Virus (HDV) Infection Among Sudanese Patients With Hepatitis B Virus |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| ENTECAVIR ANHYDROUS | 4 | 3 |
| BULEVIRTIDE | 4 | 2 |
| TENOFOVIR ALAFENAMIDE | 4 | 1 |
| ELEBSIRAN | 2 | 3 |
| TOBEVIBART | 2 | 3 |
Related Atlas pages
- Drugs: Entecavir, Bulevirtide, Tenofovir Alafenamide